295,000 Shares in Myovant Sciences Ltd (MYOV) Acquired by Eventide Asset Management LLC

Eventide Asset Management LLC purchased a new position in shares of Myovant Sciences Ltd (NASDAQ:MYOV) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 295,000 shares of the company’s stock, valued at approximately $3,463,000. Eventide Asset Management LLC owned approximately 0.49% of Myovant Sciences at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Deerfield Management Co. purchased a new stake in Myovant Sciences during the fourth quarter worth approximately $18,619,000. RA Capital Management LLC raised its stake in Myovant Sciences by 56.6% in the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after buying an additional 848,422 shares in the last quarter. Norges Bank purchased a new stake in Myovant Sciences during the fourth quarter worth approximately $9,763,000. Perceptive Advisors LLC purchased a new stake in Myovant Sciences during the fourth quarter worth approximately $2,815,000. Finally, BB Biotech AG raised its stake in Myovant Sciences by 3.4% in the first quarter. BB Biotech AG now owns 3,302,835 shares of the company’s stock worth $38,775,000 after buying an additional 110,000 shares in the last quarter.

Institutional Ownership by Quarter for Myovant Sciences (NASDAQ:MYOV)

Myovant Sciences Ltd (NASDAQ MYOV) traded down 3.43% during midday trading on Tuesday, reaching $11.26. 82,021 shares of the company were exchanged. Myovant Sciences Ltd has a 52 week low of $10.25 and a 52 week high of $15.50. The company has a 50-day moving average of $12.82 and a 200 day moving average of $11.83. The firm’s market capitalization is $678.75 million.

TRADEMARK VIOLATION NOTICE: “295,000 Shares in Myovant Sciences Ltd (MYOV) Acquired by Eventide Asset Management LLC” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://sportsperspectives.com/2017/06/20/295000-shares-in-myovant-sciences-ltd-myov-acquired-by-eventide-asset-management-llc.html.

Separately, Zacks Investment Research lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.20.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply